The stock of Artivion Inc. (NYSE:AORT) last traded at $12.78, down -0.78% from the previous session.
Data from the available sources indicates that Artivion Inc. (NYSE:AORT) is covered by 6 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $30.75 and a low of $14.00, we find $24.00. Given the previous closing price of $12.88, this indicates a potential upside of 86.34 percent. AORT stock price is now 2.83% away from the 50-day moving average and -24.92% away from the 200-day moving average. The market capitalization of the company currently stands at $519.38M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 1 analysts have assigned it a hold rating, and 5 have given it a buy rating. Brokers who have rated the stock have averaged $23.13 as their price target over the next twelve months.
With the price target reduced from $32 to $28, Lake Street maintained Buy rating for Artivion Inc. (NYSE: AORT). On August 08, 2022, Lake Street recently initiated its ‘Buy’ rating on the stock quoting a target price of $32, while ‘Stifel’ rates the stock as ‘Buy’.
In other news, Horton Amy, VP, Chief Accounting Officer sold 3,226 shares of the company’s stock on Dec 14. The stock was sold for $43,783 at an average price of $13.57. Upon completion of the transaction, the VP, Chief Accounting Officer now directly owns 101,950 shares in the company, valued at $1.3 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 16, VP, Quality Maney Rochelle L. sold 7,161 shares of the business’s stock. A total of $164,409 was realized by selling the stock at an average price of $22.96. This leaves the insider owning 12,325 shares of the company worth $0.16 million. Insiders disposed of 116,184 shares of company stock worth roughly $1.48 million over the past 1 year. A total of 3.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AORT stock. A new stake in Artivion Inc. shares was purchased by NATIXIS during the first quarter worth $717,000. DYNAMIC TECHNOLOGY LAB PRIVATE LTD invested $311,000 in shares of AORT during the first quarter. In the first quarter, AMALGAMATED FINANCIAL CORP. acquired a new stake in Artivion Inc. valued at approximately $240,000. GRAHAM CAPITAL MANAGEMENT, L.P. acquired a new stake in AORT for approximately $192,000. OCCUDO QUANTITATIVE STRATEGIES LP purchased a new stake in AORT valued at around $133,000 in the second quarter. In total, there are 217 active investors with 89.70% ownership of the company’s stock.
With an opening price of $12.83 on Friday morning, Artivion Inc. (NYSE: AORT) set off the trading day. During the past 12 months, Artivion Inc. has had a low of $9.64 and a high of $23.43. As of last week, the company has a debt-to-equity ratio of 1.22, a current ratio of 5.20, and a quick ratio of 3.60. The fifty day moving average price for AORT is $12.45 and a two-hundred day moving average price translates $16.98 for the stock.
The latest earnings results from Artivion Inc. (NYSE: AORT) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at -$0.11, missing analysts’ expectations of -$0.07 by -0.04. This compares to $0.24 EPS in the same period last year. The net profit margin was -13.10% and return on equity was -14.50% for AORT. The company reported revenue of $76.84 million for the quarter, compared to $72.21 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.41 percent. For the current quarter, analysts expect AORT to generate $76.19M in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/18/2015. Investors who held shares on 12/11/2015 were paid a $0.03 dividend.
Artivion Inc.(AORT) Company Profile
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
